Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer

Executive Summary

In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.

Advertisement

Related Content

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer
Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi Releases Annual Drug Price Report Ahead Of Senate Hearing
Sanofi Poised To File Isatuximab In Multiple Myeloma, Going Up Against J&J's Darzalex
Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Sanofi's Vaccines Performance Helps Offset Diabetes Decline
TMB Biomarker Is A Winding Path Rather Than Straight Road
Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel